## TIPS FOR ENROLLMENTS, PRIOR AUTHORIZATIONS, AND APPEALS: ANSWERING KEY QUESTIONS

Every insurance plan is different. Coverage determinations are individualized and based upon the patient's clinical history, relevant testing, and your independent medical evaluation of the patient.

Janssen

**Care**Path

Contact your Janssen Therapy Access Manager for information about plan-specific policies and coverage criteria, or if any further assistance is needed.

## **IMPORTANT QUESTIONS FOR COVERAGE DETERMINATION:**

- What is the patient's diagnosis?
- Does the patient have comorbidities?
- What is the patient's WHO Group?
- What is the patient's WHO Functional Class?
- What diagnostic tests have been performed to confirm this diagnosis?
  - Was a right-heart catheterization (RHC) test performed? If not, why?
  - Was vasoreactivity testing performed?
  - Has the patient had recent lab tests (HGB/HCT, LFTs, BNP, pregnancy test)?
- What are the patient's clinical symptoms?
- Which pulmonary arterial hypertension (PAH) therapies are currently being prescribed?
  - Phosphodiesterase type-5 (PDE-5) inhibitors/soluble guanylate cyclase stimulators (sGCs)
  - Endothelin receptor antagonists (ERAs)
  - Prostacyclin pathway agents
  - Conventional therapies
- How is the patient responding to current therapies?
- Has the patient's clinical status changed?
- Is patient currently hospitalized? If recently discharged, list discharge date
- Which PAH therapies have been tried and failed? Does the patient have any contraindication(s) to preferred formulary medications?
- What is the clinical rationale for not choosing other PAH therapies on the formulary?
- What is the clinical rationale for the change in the patient's treatment plan?
- What is the clinical rationale for choosing the requested therapy?

The questions above highlight items and information that may be needed to obtain a coverage decision from an insurer: The list is neither medical guidance nor a suggestion that you submit an appeal. The information provided on this list is general in nature and is not intended to be conclusive or exhaustive. As the patient's healthcare provider, you are responsible for applying your clinical judgment regarding appropriate care and treatment of each patient.

The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. It is not intended to increase or maximize reimbursement by any payer. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. Please refer to the applicable plan's website, or contact the plan for more information about coverage or any restrictions or prerequisites that may apply. We strongly recommend you consult the payer organization for its reimbursement policies.



©2020 Actelion Pharmaceuticals US, Inc. All rights reserved. cp-115643v3 1120